ArticlePloS one2019
Mental health professionals' views and experiences of antipsychotic reduction and discontinuation.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Medication Growth Following Diagnosis of Intellectual and Developmental Disabilities at Varying Ages Throughout Childhood.Pharmacoepidemiology and drug safety · 2026Article
- [Reduction and discontinuation of antipsychotic drugs in outpatient practice: perspectives of psychiatrists].Der Nervenarzt · 2026Article
- Dose reduction and discontinuation of antipsychotics in psychotic disorders: a systematic review of qualitative studies and meta-synthesis.Schizophrenia (Heidelberg, Germany) · 2026Review
- Helping people to discontinue antipsychotics: if, when and how.Schizophrenia (Heidelberg, Germany) · 2025Review
- Consumers' and practitioners' perspectives on the antipsychotic induced metabolic syndrome and challenges in metabolic monitoring to patient prescribed second generation antipsychotics in severe mental illness.Journal of health psychology · 2025Article
- Review
- 'I Wish It Were More Often Told to People Before They Are Prescribed These Medications How Hard It Is to Get Off Them': A Qualitative Descriptive Analysis of Free-Text Responses to a Survey on Reducing and Stopping Psychiatric Medication.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- From Idealist to Realist-Designing and Implementing Shared Decision-Making Interventions in the Choice of Antipsychotic Prescription in People Living with Psychosis (SHAPE): A Realist Review.Schizophrenia bulletin · 2025Review
- Review
- Autoethnographic Reflections on Mental Distress and Medication Management: Conceptualising Biomedical and Recovery Models of Mental Health.Community mental health journal · 2025Article
- Antipsychotic management in general practice: serial cross-sectional study (2011-2020).The British journal of general practice : the journal of the Royal College of General Practitioners · 2025Article
- Difficulties in monitoring cardiometabolic risk in the chronic use of atypical antipsychotics for non-traditional indications, in a specialty hospital in Argentina: a qualitative study.Archivos de cardiologia de Mexico · 2025Article
- Article
- Article
- Mental Health Staff's Perspectives on Tapering of Antipsychotic Medication: A Focus Group Study.Qualitative health research · 2023Article
- Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial.EClinicalMedicine · 2023Article
- The experiences of 585 people when they tried to withdraw from antipsychotic drugs.Addictive behaviors reports · 2022Article
- An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders.BMC psychiatry · 2022Article
- A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.Schizophrenia bulletin · 2021Article
- Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs.Schizophrenia bulletin · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe widely established treatment for psychosis is long-term antipsychotic medication. However, many people stop taking this treatment, and request other options. There are also growing concerns about adverse effects, but currently no professional guidelines to support reducing or stopping these drugs. The views and experiences of individual mental health professionals around reducing and stopping antipsychotics are therefore crucial in treatment decisions.
methodsWe conducted 7 focus groups with prescribing psychiatrists and other members of community-based statutory mental health services in London. Participants discussed their views about, experiences, and processes of antipsychotic reduction and discontinuation. Data were analysed using thematic analysis.
resultsParticipants acknowledged that antipsychotics can have severe adverse effects. They were generally supportive of trying to reduce these drugs to the lowest effective dose, although stopping antipsychotics was less acceptable. Prior experiences of adverse events after reduction or discontinuation meant that both were approached with caution. Reduction was also reported to be hampered by organisational and knowledge barriers. Lack of resources, pressure to discharge, and poor continuity of care were seen as organisational barriers. Knowledge barriers included inadequate evidence about who might be best suited to reduction, and lack of guidance about how this could be done safely. This meant that reduction was often prompted by patients, and sometimes actively discouraged, and stability with maintenance treatment was often favoured.
conclusionsConcerns about risk and other barriers means that clinicians are often reluctant to implement reduction or discontinuation of antipsychotic medication. In order to increase the treatment options available to service users, more research and guidance on how to minimise the risks of antipsychotic reduction and discontinuation is required to enable clinicians to engage more constructively with service users requests, offering people more choice and control in managing their mental health condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.